Ortega M, Marco F, Soriano A, Almela M, Martínez J A, Muñoz A, Mensa J
Servicio de Microbiología, Hospital La Fe, Valencia.
Rev Esp Quimioter. 2008 Jun;21(2):93-8.
A greater rate of treatment failures with vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia has been reported recently when the minimum inhibitory concentration (MIC) is > or =2 mg/l. This study has aimed to evaluate if there are clinical and/or epidemiological factors that predict isolation of a MRSA strain with MIC of vancomycin of > or =2 mg/L in the bacteremia episodes collected during a 15 year period (January 1991 to December 2005) in a tertiary urban hospital. During the study period, a total of 478 episodes of MRSA bacteremia were studied prospectively. The following clinical variables were recorded for each one: age, gender, comorbidity, previous administration of vancomycin or another antibiotic, prognosis of baseline diseases, bacteremia focus, shock, empiric antibiotic received and mortality. The MIC of vancomycin of 419 strains (88%) was determined with the E-test. In 216 (52%) of the isolations the MIC of vancomycin was 1.50 mg/L, in 110 (26%) of the cases it was < or =1 mg/l and in 93 (22%) 2 mg/l. Uni-and multivariate analyses were made, comparing the clinical variables of the patients infected by strains with MIC of vancomycin > or =2 mg/l regarding the MIC strains < or =1 mg/l. In the last 3 years of the study (2003-2005) the proportion of the strains with MIC of vancomycin > or =2 mg/l was significantly greater than those isolated with MIC < or = 1 mg/L (44 % vs 3 %; p<0.001). In the multivariate analysis, the only clinical characteristic associated independently to the isolation of a strain with MIC > or =2 mg/l was the nosocomial-acquired infection OR (95 % CI): 1.94 (1.04-3.63); p=0.04. Although the isolation of a MRSA strain with MIC of vancomycin > or =2 mg/l is more frequent in the nosocomial-acquired bacteremia episodes, in the clinical practice, it is not a useful predictive parameter because the frequency of isolation of these strains in the community is also high.
最近有报道称,在耐甲氧西林金黄色葡萄球菌(MRSA)菌血症中,当万古霉素的最低抑菌浓度(MIC)≥2mg/L时,治疗失败率更高。本研究旨在评估在一家城市三级医院15年期间(1991年1月至2005年12月)收集的菌血症发作中,是否存在临床和/或流行病学因素可预测分离出万古霉素MIC≥2mg/L的MRSA菌株。在研究期间,前瞻性地研究了总共478例MRSA菌血症发作。记录了每例患者的以下临床变量:年龄、性别、合并症、先前是否使用过万古霉素或其他抗生素、基线疾病的预后、菌血症病灶、休克、经验性使用的抗生素以及死亡率。用E-test法测定了419株(88%)菌株的万古霉素MIC。在216例(52%)分离株中,万古霉素MIC为1.50mg/L,110例(26%)病例中MIC≤1mg/L,93例(22%)为2mg/L。进行了单因素和多因素分析,比较了万古霉素MIC≥2mg/L菌株感染患者与MIC≤1mg/L菌株感染患者的临床变量。在研究的最后3年(2003 - 2005年),万古霉素MIC≥2mg/L的菌株比例显著高于MIC≤1mg/L的分离株(44%对3%;p<0.001)。在多因素分析中,与分离出MIC≥2mg/L菌株独立相关的唯一临床特征是医院获得性感染,比值比(95%可信区间):1.94(1.04 - 3.63);p = 0.04。尽管在医院获得性菌血症发作中,分离出万古霉素MIC≥2mg/L的MRSA菌株更为常见,但在临床实践中,它并不是一个有用的预测参数,因为这些菌株在社区中的分离频率也很高。